Replies to post #12852 on Ariad Pharmaceuticals Inc fka ARIA

[NP1986]

If approved as a front line therapy, what would be the size of the market?

The front line market potential is >$2 billion and growing. The problem is ponatinib would be facing competition against second generation agents like Tasigna and Sprycel, and against Gleevec which would be available as a generic by the time Ariad completes a head-to-head phase III trial.